BEY2153

DRUG2 trials

Sponsors

BeyondBio Inc.

Conditions

Alzheimer DiseaseAlzheimer' DiseaseAlzheimer's Disease

Phase 1

A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants

CompletedNCT04476303

BeyondBio Inc.Alzheimer's Disease

Start: 2020-08-27End: 2021-11-23Updated: 2025-03-10

Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease

Not yet recruitingNCT06885567

BeyondBio Inc.Alzheimer' Disease, Alzheimer Disease

Start: 2025-07-31End: 2028-08-31Target: 90Updated: 2025-03-20